The TP53 gene is mutated in around 50% of cancer cells, but in addition to its role in tumor suppression, cancer cells ...

A large international study led by researchers at Memorial Sloan Kettering has immediate clinical relevance for risk assessment and treatment of people with myelodysplastic syndrome and acute myeloid ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

TP53 is a gene located on chromosome 17 that, when normal, stops cells from growing and dividing. You can inherit a TP53 mutation from your parents or develop one later in life. An inherited TP53 ...

Patients with myelofibrosis (MF) with single-hit mutations had similar outcomes to patients with wild-type TP53. People with myelofibrosis (MF) who undergo hematopoietic stem cell transplantation ...

The TP53 is a gene that instructs the cell to produce tumor protein (p53) ; a vital transcription factor and tumor suppressor. P53 is known as the “guardian of the genome” as it helps in regulating ...

Confirmed responses were observed in patients whose tumors were TP53 Y220C mutated and KRAS wild-type in eight tumor types, including ovarian, lung, breast, endometrial, head and neck, colorectal, ...

Mutations in the tumor suppressor gene TP53 have been found in 90 percent of osteosarcomas, suggesting the alteration plays a key role early in development of the bone cancer. The discovery that TP53 ...